We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Houlihan Lokey, Crocs and Community Health Systems
Read MoreHide Full Article
For Immediate Release
Chicago, IL – February 4, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Houlihan Lokey (HLI - Free Report) , Crocs (CROX - Free Report) and Community Health Systems (CYH - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
A Window to Buy 3 Great Stocks Ahead of Earnings
We came into this earnings season with a lot of things on our minds. In fact, we were thinking of everything other than earnings. But over the past couple of weeks, America Inc. has put on a great show.
So now we know that yes, supply chains are going to take time to iron out, labor is going to remain tight (the JOLTS report shows increasing vacancies and declining quits in December) and a hawkish Fed is going to do its thing. But that isn’t going to be enough to stop the growth, albeit at a slower rate than we’ve seen of late.
And here’s the thing: the Fed may be hawkish, but it’s extremely unlikely to take any action that could throw us into a recession. Inflation is much stronger than that. So while interest rates are going to ride higher, it’s likely to be gradual and it’s likely to be upon consideration of the current situation.
So. This, then, becomes a great opportunity to buy stocks. And after the correction through January and a miss from our favorite social media company, it’s become much easier.
The thing to keep in mind is, we don’t need to find the bottom. It’s a much better idea to find obvious indicators of underlying strength -- at valuations that are off their recent highs. That’s what we’re doing here.
This selection focuses on companies that have not yet reported. But they’ve seen some strong estimate revisions of late, a sign of improving factors that have been picked up by brokers.
Let’s take a look at Houlihan Lokey for example. The investment banking company, which provides merger and acquisition (M&A), capital market, financial restructuring, and financial and valuation advisory services worldwide reported very strong results in the last quarter, beating EPS estimates by around 44% on revenue that also beat by 44%.
A quick look at Houlihan Lokey’s estimate revisions trend shows notable increases: by 40 cents (22%) for the December quarter that the company is set to report on Feb 8. Estimates for the year ending in March 2022 are up 56 cents (9%). And similarly for fiscal 2023.
A look at the price chart shows continued declines since the middle of January. It just doesn’t make sense. Particularly because on a P/E basis, they are trading at around 16.7X, which is close to their lows over the past year.
So this looks like a Strong Buy, captured in the Zacks #1 rank.
Another stock that seems to fit the bill is Crocs, which manufactures and sells casual footwear and accessories for men, women and children in over 80 countries.
In the last quarter, Crocs generated earnings that beat the Zacks Consensus Estimate by 30% coming on top of revenues that beat by about 2%.
The estimate revisions trend for the December quarter (to be reported on Feb 16) shows an increase of 63 cents (46%) in the last 30 days. For the full year ending December 2021, the estimate is up 59 cents (78%). The growth trajectory looks set to repeat this year with the average estimate up 70 cents (7%) during the same time period.
Now let’s see what prices are doing. I’m seeing a steady decline in Crocs shares since the beginning of November, down almost 42% in the last three months with a slight bounce-back in the last couple of days. This is reflected in the valuation, which at around 10.1X P/E, is also hugging the low point over the past year.
No wonder Crocs looks like a strong buy and it has a Zacks rank to match.
Next on the list is Community Health Systems which owns, leases and operates general acute care hospitals in the U.S.
In the last quarter, Community Health posted a 69-cent profit when analysts were only expecting 5 cents. That’s a huge surprise of 1280%, driven by a surge in COVID-related hospitalizations. Estimates are tracking closer to reality since then and have been climbing steadily over the last few months. In the last 30 days, the December quarter consensus is up 8 cents (19%) while the 2022 estimate is up 14 cents (12%).
Community Health shares dipped in the beginning of December but have trended up since then. The valuation based on P/E shows that they are still rather undervalued at a 9.57X multiple. A strong report when the company reports on Feb 16 would send the shares higher.
As with the other two, Community Health also carries a Zacks Rank #1.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?
From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Houlihan Lokey, Crocs and Community Health Systems
For Immediate Release
Chicago, IL – February 4, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Houlihan Lokey (HLI - Free Report) , Crocs (CROX - Free Report) and Community Health Systems (CYH - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
A Window to Buy 3 Great Stocks Ahead of Earnings
We came into this earnings season with a lot of things on our minds. In fact, we were thinking of everything other than earnings. But over the past couple of weeks, America Inc. has put on a great show.
So now we know that yes, supply chains are going to take time to iron out, labor is going to remain tight (the JOLTS report shows increasing vacancies and declining quits in December) and a hawkish Fed is going to do its thing. But that isn’t going to be enough to stop the growth, albeit at a slower rate than we’ve seen of late.
And here’s the thing: the Fed may be hawkish, but it’s extremely unlikely to take any action that could throw us into a recession. Inflation is much stronger than that. So while interest rates are going to ride higher, it’s likely to be gradual and it’s likely to be upon consideration of the current situation.
So. This, then, becomes a great opportunity to buy stocks. And after the correction through January and a miss from our favorite social media company, it’s become much easier.
The thing to keep in mind is, we don’t need to find the bottom. It’s a much better idea to find obvious indicators of underlying strength -- at valuations that are off their recent highs. That’s what we’re doing here.
This selection focuses on companies that have not yet reported. But they’ve seen some strong estimate revisions of late, a sign of improving factors that have been picked up by brokers.
Let’s take a look at Houlihan Lokey for example. The investment banking company, which provides merger and acquisition (M&A), capital market, financial restructuring, and financial and valuation advisory services worldwide reported very strong results in the last quarter, beating EPS estimates by around 44% on revenue that also beat by 44%.
A quick look at Houlihan Lokey’s estimate revisions trend shows notable increases: by 40 cents (22%) for the December quarter that the company is set to report on Feb 8. Estimates for the year ending in March 2022 are up 56 cents (9%). And similarly for fiscal 2023.
A look at the price chart shows continued declines since the middle of January. It just doesn’t make sense. Particularly because on a P/E basis, they are trading at around 16.7X, which is close to their lows over the past year.
So this looks like a Strong Buy, captured in the Zacks #1 rank.
Another stock that seems to fit the bill is Crocs, which manufactures and sells casual footwear and accessories for men, women and children in over 80 countries.
In the last quarter, Crocs generated earnings that beat the Zacks Consensus Estimate by 30% coming on top of revenues that beat by about 2%.
The estimate revisions trend for the December quarter (to be reported on Feb 16) shows an increase of 63 cents (46%) in the last 30 days. For the full year ending December 2021, the estimate is up 59 cents (78%). The growth trajectory looks set to repeat this year with the average estimate up 70 cents (7%) during the same time period.
Now let’s see what prices are doing. I’m seeing a steady decline in Crocs shares since the beginning of November, down almost 42% in the last three months with a slight bounce-back in the last couple of days. This is reflected in the valuation, which at around 10.1X P/E, is also hugging the low point over the past year.
No wonder Crocs looks like a strong buy and it has a Zacks rank to match.
Next on the list is Community Health Systems which owns, leases and operates general acute care hospitals in the U.S.
In the last quarter, Community Health posted a 69-cent profit when analysts were only expecting 5 cents. That’s a huge surprise of 1280%, driven by a surge in COVID-related hospitalizations. Estimates are tracking closer to reality since then and have been climbing steadily over the last few months. In the last 30 days, the December quarter consensus is up 8 cents (19%) while the 2022 estimate is up 14 cents (12%).
Community Health shares dipped in the beginning of December but have trended up since then. The valuation based on P/E shows that they are still rather undervalued at a 9.57X multiple. A strong report when the company reports on Feb 16 would send the shares higher.
As with the other two, Community Health also carries a Zacks Rank #1.
Just Released: Zacks Top 10 Stocks for 2022
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?
From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab.
See Stocks Now >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.